Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study

Marc HumbertCamille TailléLaurence MalaVincent Le GrosJocelyne JustMathieu Molimard

Abstract

Omalizumab is a monoclonal anti-IgE antibody used to treat severe allergic asthma (SAA). The aim of the STELLAIR study was to determine the importance of pre-treatment blood eosinophil count as a predictive measure for response to omalizumab.

This retrospective real-life study was conducted in France between December 2015 and September 2016 using medical records of SAA omalizumab-treated patients. Response to omalizumab was assessed by three criteria: physician evaluation, reduction of ≥40% in annual exacerbation rate and a combination of both. Response rate was calculated according to blood eosinophil count measured in the year prior to omalizumab initiation.

872 SAA omalizumab-treated patients were included by 78 physicians (723 adults (age ≥18 years) and 149 minors (age 6–17 years)). Blood eosinophil count was ≥300 cells·µL−1 in 52.1% of adults and 73.8% of minors. By physician evaluation, 67.2% of adults and 77.2% of minors were responders and 71.1% adults and 78.5% minors had a ≥40% reduction in the exacerbation rate. In adults, the response rate for combined criteria was 58.4% (95% CI 53.2–63.4%) for blood eosinophils ≥300 cells·µL−1 (n=377) and 58.1% (95% CI 52.7–63.4%) for blood eosinophils <300 cells·µL−1 (n=346).

This study shows that a large proportion of patients with SAA have a blood eosinophil count ≥300 cells·µL−1, and suggests that omalizumab effectiveness is similar in “high” and “low” eosinophil subgroups.


Full Text (PDF)

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma RT @EAACI_HQ: Assessing severity of #anaphylaxis: pros and cons of the multiple #anaphylaxis severity-scoring instruments used in literatur…
8hreplyretweetfavorite
Interasma RT @IPCRG: Implementation pack nearly ready. We hope to have it running too! Fantastic experiences to share from Canada, Spain, Portugal…
8hreplyretweetfavorite
Interasma RT @KulikovUNIATF: India’s toxic air claimed 1.24 million lives in 2017, or 12.5% of total deaths recorded that year. #airpolluton #BeatNCD
8hreplyretweetfavorite
Interasma RT @Aller_MD: Epicutaneous immunotherapy in rhino-conjunctivitis and food allergies: a review of the literature https://t.co/4j8S7Ee4p5
8hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma